Framework Programme 7

2. Framework Programme 7

3. Capacity

4. Capacity

5. Supporting Actions • Activities in a Support action may cover • Individual events: conferences, seminars, working groups and expert groups; Studies, analysis; • Fact findings and monitoring; Preparatory technical work, including feasibility studies; Development of research or innovation strategies; • High level scientific awards and competitions; • Operational support, data access and dissemination, information and communication activities • (Support actions do not conduct S&T research !) • Experience of SSAs in FP6 • Average duration: 9-30 months • Optimum consortium: 1-15 participants • Total EC contribution: 0.03-3 M€

6. Coordination Actions • Activities in a Coordination action may cover • Networking, coordination and dissemination activities • Management of the consortium • (Coordination actions do not conduct S&T research !) • Experience of CAs in FP6 • Average duration: 18-36 months • Optimum consortium: 13-26 participants • Total EC contribution: 0.5-2 M€

7. Centar za funkcionalnu genomiku • osnovan 2002 u svrhu promicanja translacijskih istraživanja kako bi se olakšala suradnja bazičnih i kliničkih znanstvenika • zajednički projektMedicinskog fakulteta, Kliničkog bolničkog centra “Zagreb”i Harvard Medical School

8. Centar za funkcionalnu genomiku

9. Centar za funkcionalnu genomiku

10. Tehnologija • Ekspresijsko profiliranje • Chromatin Immunoprecipitation on Chip (ChIP-CHIP) • Comparative Genomic Hybridization (CGH) • SNP analysis using 500K Affymetrix microarrays • Roche LightCycler real-time RT-PCR i klasični PCR • kultura stanica • transfekcije primarnihkultura i staničnih linija • Western blotting, imunohistokemijske metode • provjera kvalitete RNA pomoću Agilent Bioanalyzer

11. Projekti • Krvni biomarkeri za Huntingtonovubolest • Krvni testovi za Parkinsonovubolest • Genomska analiza transkriptomai interaktomau bolesnika s kompleksnim bolestima • Razvoj novih biomarkera za bolesnike sa shizofrenijom • Dijegnostilki i prognostički krvni markeri u bolesnika s multiplom sklerozom i retrobulbarnim neuritisom • Molekularni mehanizmi osteoporoze • Molekularna osnova CD34 pozitivnih akutnih mijeloidnih leukemija

12. Suradnja • Harvard Medical School, Boston, USA • Ludwig Maximilian University, Munich, Germany • University of Tübingen, Tübingen, Germany • Institute for Molecular Medicine, Lisabon, Portugal • Tel-Aviv University, Tel-Aviv, Israel • Medical Research Council Human Genetics Unit, Edinburgh, UK • University of Edinburgh, Edinburgh, UK

13. Odabrana publikacije • Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 127:59-69. 2006. • Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.Proc Natl Acad Sci U S A. 102:11023-8. 2005. • Paralkar VM, Borovecki F, Ke HZ, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 100:6736-40. 2003.

14. Call identifier: FP7-REGPOT-2007-1 Date of publication: 22 December 2006 Deadline: 24 April 2007, at 17 h, Brussels local time Indicative budget: 22 M€

16. Detalji poziva The FP7 “Capacities Work Programme: Research Potential” states under the specific topic REGPOT-2007-1: “This activity will give the possibility to improve the research capacities of highest quality and/or promising centres, in the thematic priorities’ domains of the FP7, by reinforcing their S&T potential, by supporting and mobilising the human and material resources, bydeveloping strategic partnerships (including twinning) with well established research groupselsewhere in the Union, by disseminating scientific information as well as the results ofresearch, by facilitating communication between the centres having similar scientific interest and by improving their responses to socio-economic needs of the country.“

17. GRACE • Genomic Research for Anthropology, Clinical medicine and Epidemiology (GRACE) • Datumpripreme: 03 ožujka 2005 • Vrsta projekta: Specific Support Actions (SSA)

18. GRACE

19. INTEGERS INTEgrating and Strengthening GEnomic Research in South-Eastern Europe – INTEGERS

20. INTEGERS

21. INTEGERS - Objectives • strengthening and expanding the existing research infrastructure • reinforcing the existing collaborations and knowledge transfer • providing interested young researchers with employment opportunities • dissemination of research results • implementation of research results

22. INTEGERS – WP1

23. INTEGERS – WP2

24. INTEGERS – WP3

25. INTEGERS – WP4

26. INTEGERS – WP4

27. INTEGERS – WP5

28. Podnošenje projekta • Točno određeno vrijeme • 17h00 obično utorkom, prema vremenu u Bruxelles-u • Podnošenje jednim postupkom • Elektronsko podnošenje prijedloga projekta • EPSS (Electronic Proposal Submission System)

29. EPSS • Svi prijedlozi projekta podnose se elektronski krozElectronic Proposal Submission Service (EPSS) • Part A – ispunjava se on-line • Part B – unosi se u obliku PDF file-a; sadrži detalje prijedloga projekta

30. Evaluacijski kriteriji • Tri glavna kriterija • S&T Quality • koncept, ciljevi, izvedbeni plan • Implementation • Opis sudionika projekat • Raspodjela i korištenje sredstava • Impact • Doprinos predviđenim učincima prema tekstu natječaja • Plan za diseminaciju/eksploataciju

31. Evaluacija

32. Evaluacija

34. Negotiation • Potrebno dostaviti dodatne dokumente (o pravnom statusu ustanove, o bankovnom računu) • Dorada izvedbenog plana projekta (Annex I – Description of Work, Grant Agreement Preparation Form – GPF) • Pregovori oko financijskih sredstava – EK u pravilu smanjuje iznos traženih sredstava